CVM:NYSEMKT, CEL-SCI Corporation

Why CVM stock rose on November 16

CEL-SCI Corporation rose 29.7% on Monday, November 16, 2026, on 1,156,144 shares, 6.6 times its average daily volume. No headline about CVM came out that day or the day before in the news feeds we follow, so the move may come from news we don't track, the sector or trading alone.

CVM stock overview

CEL-SCI Corporation (CVM:NYSEMKT) closed at $1.66 on November 16, 2026, up 29.69% on the day. The stock trades 78.7% below its 52-week high of $7.80 and 86.5% above its 52-week low of $0.890. Over the past year, it lost 74.5%. CEL-SCI Corporation is part of the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)).

Key figures

Price
$1.66
Day change
+29.69%
Volume
1,156,144
Average volume
175,050
Market cap
29M+
52-week range
$0.890 – $7.80
50-day average
$1.66
200-day average
$2.29

Price action over the past year

In 252 trading sessions since November 14, 2025, CVM closed higher on 114 days (45%). Its best day was November 16, 2026 (+29.69%) and its worst was May 4, 2026 (-25.88%). The stock moved 10% or more in a single session 31 times.

Recent signals

CVM news

About CEL-SCI Corporation

CEL-SCI Corporation engages in the research and development of drugs and vaccines. Its lead investigational immunotherapy is Multikine, which is under pivotal phase III clinical trial for the treatment of primary head and neck cancer. The company's Multikine is also used in a Phase I study with the Naval Medical Center, San Diego under a cooperative research and development agreement in HIV/HPV co-infected men and women with peri-anal warts. Its Ligand Epitope Antigen Presentation System, a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza in hospitalized patients; and CEL-2000 and CEL-4000 vaccine product candidates for the treatment of rheumatoid arthritis. CEL-SCI Corporation was founded in 1983 and is headquartered in Vienna, Virginia.

Similar stocks

Find more stocks like CVM with the Spikes, Gaps, Breakouts and Performance Tracker scanners.

Based on end-of-day data. For information only, not investment advice.